Empowering Healthcare, one diagnostic at a time, through accessible and affordable solutions.

**Investment**

- **Series**: Seed
- **Raise**: $3M
- **Capital Raised**: $0.6M
- **Minimum**: $100K

**Use of Funds:**
- Clinical and Regulatory: 83%
- Company Systems: 3%
- Headcount: 7%

**Team**

- **Chiao-ih Hui**: Founder and CEO
- **Duke Heninger**: Chief Financial Officer
- **Matthew McGaw**: VP Business Development
- **Marcus Osborne**: Strategic Advisor

**Overview**

Solution Diagnostics is currently conducting clinical trials in the US for 4SureRapid™ 4-in-1 Rapid Antigen Test for COVID-19, Flu A, Flu B, and RSV. Walmart and CVS are working towards private-labeling the test and other Retailers are waiting to purchase and include in their stores.

**Highlights**

- Immediate sales channel of Retail Market is over 15,000 retail locations
- Technical partner is publicly-traded company in Taiwan founded in 1976

**Competition**

The only other rapid antigen OTC tests detect COVID-19 only, while tests that include COVID-19, Flu A, Flu B, and RSV require a minimum of 1-2 days after receiving the sample in the lab.

**Market**

Total Addressable Market: $11B Annually

- Retailer 74%
- Clinics 8%
- Schools 6%
- Telehealth 4%
- Prisons 8%

**Financials**

- Based upon Retailer forecasts, financial forecast assumes 400 tests / month / store. Not including respiratory illness season sees a ramp of 1200 tests / month / store
- PO Financing for COGS already lined up

<table>
<thead>
<tr>
<th>PRO-FORMA</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue (K)</td>
<td>$25,600</td>
<td>$96,000</td>
<td>$232,000</td>
<td>$422,400</td>
</tr>
<tr>
<td>COGS (K)</td>
<td>$13,152</td>
<td>$49,320</td>
<td>$119,190</td>
<td>$217,008</td>
</tr>
<tr>
<td>Gross Profit (K)</td>
<td>$12,488</td>
<td>$46,680</td>
<td>$112,810</td>
<td>$205,392</td>
</tr>
<tr>
<td>Gross Margin %</td>
<td>48.63%</td>
<td>48.63%</td>
<td>48.63%</td>
<td>48.63%</td>
</tr>
</tbody>
</table>